Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LNTH 
Lantheus Holdings Inc (LNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: LNTH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $83.07
1 Year Target Price $83.07
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.65% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.86B USD | Price to earnings Ratio 15.11 | 1Y Target Price 83.07 |
Price to earnings Ratio 15.11 | 1Y Target Price 83.07 | ||
Volume (30-day avg) 13 | Beta 0.09 | 52 Weeks Range 47.25 - 111.29 | Updated Date 11/4/2025 |
52 Weeks Range 47.25 - 111.29 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When - | Estimate 1.28 | Actual - |
Profitability
Profit Margin 17.82% | Operating Margin (TTM) 23.27% |
Management Effectiveness
Return on Assets (TTM) 13.34% | Return on Equity (TTM) 24.71% |
Valuation
Trailing PE 15.11 | Forward PE 8.68 | Enterprise Value 3502533710 | Price to Sales(TTM) 2.54 |
Enterprise Value 3502533710 | Price to Sales(TTM) 2.54 | ||
Enterprise Value to Revenue 2.3 | Enterprise Value to EBITDA 7.66 | Shares Outstanding 67994149 | Shares Floating 63181523 |
Shares Outstanding 67994149 | Shares Floating 63181523 | ||
Percent Insiders 2.24 | Percent Institutions 117.72 |
Upturn AI SWOT
Lantheus Holdings Inc
Company Overview
History and Background
Lantheus Holdings Inc. was founded in 1956 as New England Nuclear. It has evolved through various acquisitions and restructurings, becoming Lantheus Medical Imaging in 2008 and Lantheus Holdings in 2015. The company has focused on diagnostic and therapeutic radiopharmaceuticals.
Core Business Areas
- Precision Diagnostics: Develops, manufactures, and distributes diagnostic imaging agents that help physicians detect and diagnose cardiovascular, oncological, and other diseases. Includes DEFINITY and TechneLite.
- Strategic Partnerships: Collaborates with pharmaceutical and biotech companies to develop and commercialize innovative imaging agents and therapeutics.
- Radiopharmaceutical Oncology: Focuses on developing and commercializing radiopharmaceutical therapies for cancer treatment.
Leadership and Structure
The CEO is Mary Anne Heino. The organizational structure includes departments for research and development, manufacturing, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- DEFINITY: An ultrasound contrast agent used to improve the visualization of the heart during echocardiography. The market share fluctuates based on contracts and competitors, but is a significant player in its segment. Competitors: GE Healthcare, Bracco Diagnostics
- TechneLite: A technetium generator used to produce technetium-99m, a radioisotope used in various diagnostic imaging procedures. Market share varies regionally and faces competition from other generator manufacturers and centralized radiopharmacies. Competitors: Curium, NorthStar Medical Radioisotopes.
- Pylote: A PSMA-targeted PET imaging agent used for prostate cancer detection and recurrence. A relatively new product, but has a good chance for growth. Competitors: Blue Earth Diagnostics (Axumin), Progenics Pharmaceuticals (PyL).
Market Dynamics
Industry Overview
The radiopharmaceutical industry is experiencing growth driven by advancements in imaging technologies, increased prevalence of chronic diseases (e.g., cancer, cardiovascular disease), and an aging population. The market is regulated by the FDA and faces competition from both large pharmaceutical companies and specialized radiopharmaceutical manufacturers.
Positioning
Lantheus is a leading player in the diagnostic imaging market, particularly in ultrasound contrast and nuclear medicine. Its competitive advantages include its established distribution network, strong relationships with hospitals and imaging centers, and growing portfolio of innovative products.
Total Addressable Market (TAM)
The global radiopharmaceutical market is projected to reach tens of billions USD by 2030. Lantheus is well-positioned to capture a significant share of this market through its focus on innovation and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Established distribution network
- Strong relationships with healthcare providers
- Diversified product portfolio
- Experienced management team
- Innovation in radiopharmaceutical oncology
Weaknesses
- Reliance on a few key products
- Exposure to regulatory risks
- Competition from larger pharmaceutical companies
- Potential supply chain vulnerabilities
- Dependence on hospital capital spending
Opportunities
- Expanding into new geographic markets
- Developing novel radiopharmaceutical therapies
- Acquiring complementary technologies
- Partnering with pharmaceutical companies
- Increasing use of PET/CT imaging
Threats
- Generic competition
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturns
- Regulatory changes in the radiopharmaceutical space
Competitors and Market Share
Key Competitors
- GEHC
- BHC
- CURI
Competitive Landscape
Lantheus competes with larger diversified healthcare companies and specialized radiopharmaceutical manufacturers. Lantheus's strength lies in its specialized focus and established distribution network, while its competitors may have greater financial resources and broader product portfolios.
Major Acquisitions
Progenics Pharmaceuticals (PyL)
- Year: 2020
- Acquisition Price (USD millions): 250
- Strategic Rationale: Acquired PyL, a PSMA-targeted PET imaging agent, to expand its prostate cancer imaging portfolio.
Growth Trajectory and Initiatives
Historical Growth: Lantheus has demonstrated solid growth, driven by product innovation and strategic acquisitions.
Future Projections: Analysts expect continued growth for Lantheus, driven by increasing demand for diagnostic imaging and radiopharmaceutical therapies.
Recent Initiatives: Recent initiatives include the acquisition of Pylote and the expansion of its radiopharmaceutical oncology pipeline.
Summary
Lantheus Holdings is a strong player in the radiopharmaceutical market, bolstered by key product lines and strategic acquisitions. Its financial performance is solid, although reliance on a few products could be a point of vulnerability. The company should continue to innovate and capitalize on opportunities in the growing radiopharmaceutical market, while also managing competitive and regulatory challenges. Overall the company is working well with recent initiatives looking positive but needs to keep innovating to keep its market share.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and represents an opinion. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantheus Holdings Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2015-06-25 | CEO & Director Mr. Brian A. Markison | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 808 | Website https://www.lantheus.com |
Full time employees 808 | Website https://www.lantheus.com | ||
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.